Nancy Aline Hernández-Rosas , Claudia Rebeca Rivera-Yañez , Karla Mariela Hernández-Sánchez , Oscar Nieto-Yañez , Cecilia Carlota Barrera-Ortega , Gabriel Alfonso Gutiérrez-Rebolledo , Ricardo Pérez-Pastén-Borja , Nelly Rivera-Yañez , Porfirio Alonso Ruiz-Hurtado
{"title":"Integrative review of flavonoid phytosomes and their potential role in the treatment of SARS-CoV-2 infection (COVID-19), diabetes, and cancer","authors":"Nancy Aline Hernández-Rosas , Claudia Rebeca Rivera-Yañez , Karla Mariela Hernández-Sánchez , Oscar Nieto-Yañez , Cecilia Carlota Barrera-Ortega , Gabriel Alfonso Gutiérrez-Rebolledo , Ricardo Pérez-Pastén-Borja , Nelly Rivera-Yañez , Porfirio Alonso Ruiz-Hurtado","doi":"10.1016/j.afres.2025.101294","DOIUrl":null,"url":null,"abstract":"<div><div>An increasing interest in new and available alternatives to treat pathologies of global impact, such as COVID-19, diabetes, and cancer, has led to an increase in research on compounds like flavonoids. Flavonoids usually have low bioavailability, which is related to their poor solubility and permeability, and therefore, their clinical application in many pathologies is limited. In this context, the use of nanocarriers to overcome the low bioavailability of natural products is considered crucial for future preclinical and clinical research. Among the most studied nanocarriers are phytosomes. These nanocompounds comprise electrostatic interactions of phospholipids and polyphenols in a lipidic matrix, and have shown potential for improving antiviral, antidiabetic, and anticancer properties of some flavonoids. Some phytosomal formulations have been evaluated in phase I clinical trials and have shown significant improvements over the use of single flavonoids. This review aimed to provide a current overview of the use of phytosomes loaded with flavonoids and their potential applications in the treatment of emerging infections and chronic-degenerative diseases, particularly, COVID-19, diabetes, and cancer.</div></div>","PeriodicalId":8168,"journal":{"name":"Applied Food Research","volume":"5 2","pages":"Article 101294"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Food Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772502225005992","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
An increasing interest in new and available alternatives to treat pathologies of global impact, such as COVID-19, diabetes, and cancer, has led to an increase in research on compounds like flavonoids. Flavonoids usually have low bioavailability, which is related to their poor solubility and permeability, and therefore, their clinical application in many pathologies is limited. In this context, the use of nanocarriers to overcome the low bioavailability of natural products is considered crucial for future preclinical and clinical research. Among the most studied nanocarriers are phytosomes. These nanocompounds comprise electrostatic interactions of phospholipids and polyphenols in a lipidic matrix, and have shown potential for improving antiviral, antidiabetic, and anticancer properties of some flavonoids. Some phytosomal formulations have been evaluated in phase I clinical trials and have shown significant improvements over the use of single flavonoids. This review aimed to provide a current overview of the use of phytosomes loaded with flavonoids and their potential applications in the treatment of emerging infections and chronic-degenerative diseases, particularly, COVID-19, diabetes, and cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
